Odyssey Group International Inc. ODYY Archives - Page 6 of 7

ThursdayJul 07, 2022 1:23 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device candidates and two pharmaceutical products in development. The portfolio is responding to varied needs, including patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing…

WednesdayJul 06, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Optimistic About Drug/Tech IP as Industry Studies Big Pharma M&A Outlook

Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”) detection Odyssey Health Inc. is taking its brain concussion solution to a Phase 1 clinical human trial currently with possible progression to Phase 2 before the end of the year The company likewise anticipates…

FridayJul 01, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions

No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients The CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatment The global concussion market size was valued at $6.8 billion in 2019. This value is expected to rise to $8.9 billion by 2027, growing at a CAGR of 3.6% Odyssey Health (OTC: ODYY), a medical company focused on unique,…

WednesdayJun 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug

Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion Currently, concussions do not have an FDA-approved treatment Soldiers form a significant population of people who frequently experience multiple concussions throughout their career Concussion has only recently received greater attention as different parties seek to understand the condition and possible treatments Odyssey is at the forefront of this pursuit for treatment and has developed the PRV-002 drug candidate that it intends to use on the military as part of a Phase II clinical trial The company announced the formation…

MondayJun 27, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions…

FridayJun 24, 2022 12:58 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Sets Sights on US Phase II Clinical Trials with Focus on Military

Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there is insufficient evidence supporting, among other things, the optimal treatment strategies to mitigate these impacts. “Odyssey Health is working to develop treatments for concussion and other neurological disorders. Odyssey is developing the PRV-002, a novel,…

TuesdayJun 21, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Interview Addresses Company’s Focus on Development of Drug and Device Technologies to Treat Unmet Medical Needs

Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for three of the company’s four products and pending clinical testing Odyssey’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder and patients needing treatment for brain concussion injuries The drug-device combination for treating concussions is advancing in a…

WednesdayJun 15, 2022 2:20 pm

QualityStocksNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the participants did not exhibit any severe adverse events as PRV-002 was well tolerated,” a recent article reads. “The completion of the safety evaluation is the latest milestone as the company journeys toward providing concussion treatment… With the phase I clinical trial, which consists of 48…

TuesdayJun 14, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Moving to Fill Gaps in Treatment and Management of Concussion Among Military Service Members

Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concussion” Although concussion greatly impacts the military, there are significant gaps in the understanding of the optimal diagnostic, treatment, and management criteria Odyssey is looking to bridge this informational gap with its clinical trial and intends to start its U.S. Phase II trials at military training sites, subject to the FDA’s approval of the results of its Phase I study The Center…

ThursdayJun 09, 2022 12:38 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) CEO Spotlighted in RedChip Money Report Interview

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmond is slated for broadcast at 7 p.m. ET on June 11. During the interview, which is hosted by RedChip CEO Dave Gentry, Redmond discusses the company, including the development of its novel compound, which could be the first FDA-approved treatment for concussions. With more than 5 million concussions reported in the United States each year and an…

Site Search

Company Search

Tag: Odyssey Group International Inc. ODYY